Intrathecal Trials of AVXS-101 (Zolgensma) in SMA Halted
The partial hold on trials of intrathecal administration stem from safety concerns in animals and does not affect Zolgensma intravenous infusion, which is already approved for spinal muscular atrophy. Medscape Medical News